FY2026 EPS Estimates for Aethlon Medical Reduced by Analyst

Aethlon Medical, Inc. (NASDAQ:AEMD) – Stock analysts at Zacks Research decreased their FY2026 earnings per share estimates for Aethlon Medical in a report released on Wednesday, February 18th. Zacks Research analyst M. Marin now forecasts that the medical equipment provider will post earnings per share of ($10.40) for the year, down from their previous forecast of ($9.41). The consensus estimate for Aethlon Medical’s current full-year earnings is ($0.73) per share. Zacks Research also issued estimates for Aethlon Medical’s Q4 2026 earnings at ($2.47) EPS.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Aethlon Medical in a report on Wednesday, January 21st. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Reduce” and an average price target of $560.00.

Aethlon Medical Stock Performance

NASDAQ AEMD opened at $2.04 on Friday. The firm’s fifty day moving average price is $2.59 and its two-hundred day moving average price is $5.99. The stock has a market cap of $2.69 million, a PE ratio of -0.09 and a beta of 1.60. Aethlon Medical has a fifty-two week low of $1.86 and a fifty-two week high of $49.92.

Aethlon Medical (NASDAQ:AEMD) last issued its earnings results on Thursday, February 12th. The medical equipment provider reported ($2.45) EPS for the quarter, missing the consensus estimate of ($2.01) by ($0.44).

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aethlon Medical stock. Citadel Advisors LLC purchased a new stake in Aethlon Medical, Inc. (NASDAQ:AEMD) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned about 36.57% of Aethlon Medical at the end of the most recent quarter. Institutional investors and hedge funds own 1.99% of the company’s stock.

Key Aethlon Medical News

Here are the key news stories impacting Aethlon Medical this week:

• Positive Sentiment: HC Wainwright sharply improved multi‑year EPS forecasts (notably FY2027–FY2030 and quarterly 2027 estimates), signaling an expectation of smaller future losses and a clearer path to improvement — a constructive analyst view that likely lifted investor sentiment. HC Wainwright Upgrades (MarketBeat)
• Positive Sentiment: Company advancing an oncology trial with messaging that it seeks to simplify and potentially broaden the device application—clinical progress and broader market potential can support upside if results validate commercial expansion. AEMD: Advancing Oncology Trial (Yahoo Finance)
• Neutral Sentiment: Prepared remarks from a shareholder/analyst call were posted (transcript available). This provides detail for investors but doesn’t appear to contain new, market‑moving data beyond the firm’s public updates. Shareholder/Analyst Call Transcript (Seeking Alpha)
• Neutral Sentiment: Short‑interest notices in the data feed claim a “significant increase” but report 0 shares and NaN changes — the figures are inconsistent and likely unreliable, so they’re unlikely to be a real driver unless corrected.
• Negative Sentiment: HC Wainwright also lowered estimates for FY2026 and cut Q4‑2026 expectations, reflecting a worse‑than‑expected near‑term outlook; that short‑term downgrade can cap gains and keep volatility elevated. HC Wainwright Note (MarketBeat)
• Negative Sentiment: Recent reported results showed a sizable quarterly EPS loss and a miss vs. estimates, underscoring ongoing cash burn and execution risk; until consistent clinical or commercial progress is demonstrated, downside risk remains.

Aethlon Medical Company Profile

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.